Back to search
FDAFDA · Food and drugs·Recall number Z-0463-2013

Sekisui Diagnostics, Spectrolyse PAI-1 In-Vitro Diagnostic Use for the quantitative determination of Plasminogen Activator Inhibitor Type 1 in human plasma. Catalog # 101201. Spectrolyse PAI-1 is intended for the quantitative determination of Plasminogen Activator Inhibitor Type-1 (PAI-1) activity in human plasma. The test is for in vitro diagnostic use.

Published December 12, 2012 · Recall initiated: October 24, 2012

Summary

FDA records medical device Class II recall Z-0463-2013, published December 12, 2012 and initiated October 24, 2012. Recalling firm: Sekisui Diagnostics Llc; Status: Terminated; Reported quantity: 63 kits; Lot: Lot # 120827, exp 11/27/2012. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.

Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

Spectrolyse PAI-1 activity assay, producing lower than expected absorbance values 0 IU/ml standard reducing the slope of the standard curve requiring more frequent sample dilutions.

What to do

Voluntary: Firm initiated · Letter

Get an email when a new FDA recall like this is published

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Manufacturer
Sekisui Diagnostics Llc
Distributor
Nationwide Distribution-including the states of FL, IN, NC, OH, UT, and WA.
Lot
Lot # 120827, exp 11/27/2012
Risk classification
Class II
Area (FDA)
device
Country
United States

Related recalls

Questions about this recall

Was Sekisui Diagnostics, Spectrolyse PAI-1 In-Vitro Diagnostic Use for the quantitative determination of Plasminogen Activator Inhibitor Type 1 in human plasma. Catalog # 101201. Spectrolyse PAI-1 is intended for the quantitative determination of Plasminogen Activator Inhibitor Type-1 (PAI-1) activity in human plasma. The test is for in vitro diagnostic use. recalled?

Yes. FDA published recall Z-0463-2013 on December 12, 2012. Reported hazard: Spectrolyse PAI-1 activity assay, producing lower than expected absorbance values 0 IU/ml standard reducing the slope of the standard curve requiring more frequent sample dilutions.

What should I do if I have this product?

Voluntary: Firm initiated · Letter